Brief: Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab
21/07/2026 17:22
BRIEF-Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab July 21 (Reuters) - Shanghai Junshi Biosciences Co Ltd 688180.SS:
ACCEPTANCE OF SUPPLEMENTAL APPLICATION FOR TORIPALIMAB IN COMBINATION WITH CHEMOTHERAPY AS PERIOPERATIVE TREATMENT
ACCEPTANCE NOTICE ISSUED BY NMPA CHINA
Further company coverage: 688180.SS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Junshi Biosciences
See all newsBrief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA
Brief: Shanghai Junshi Biosciences's Shareholder Plans To Cut Stake
Brief: Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab